A Non-interventional Registry for Patients with Hepatitis B Virus Infection

NCT ID: NCT05051098

Last Updated: 2025-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-06

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.

Extensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies.

Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TherVacB Subgroup

No interventions. The participating study centers of the EU funded project "TherVacB" recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort.

No intervention

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hepatitis B Virus Infection

TherVacB sub-cohort:

* confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion
* HBeAg status documented for at least 6 months

Exclusion Criteria

TherVacB sub-cohort:

* age \>70 years
* co-infection with HIV, HCV (RNA positive),
* clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.)
* significant comorbidities (e.g. malignancies)
* immunosuppressive treatment (\> 40 mg Cortisol- equivalent)
* liver cirrhosis (judged clinically or based on ultrasound/transient elastography)
* History of hepatocellular carcinoma
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Union

OTHER

Sponsor Role collaborator

German Center for Infection Research

OTHER

Sponsor Role collaborator

German Liver Foundation (DLS)

UNKNOWN

Sponsor Role collaborator

Hannover Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Markus Cornberg

Role: PRINCIPAL_INVESTIGATOR

Hannover Medical School

Xavier Forns

Role: PRINCIPAL_INVESTIGATOR

Fundacio Clinic per a la Recerca Biomedica

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hannover Medical School

Hanover, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Petra Dörge

Role: CONTACT

+49511532 ext. 6057

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Petra Dörge

Role: primary

+49511532 ext. 6057

Related Links

Access external resources that provide additional context or updates about the study.

https://www.thervacb.eu/patients/the-european-hbv-patient-registry/

Website of the EU funded part of the registry

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

848223

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

05.220

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

3374-2016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Terminator 2 Register
NCT03643172 UNKNOWN
French HIV-HBV Cohort
NCT02889094 UNKNOWN